AZGP1 deficiency promotes angiogenesis in prostate cancer
Ru M. Wen,Zhengyuan Qiu,G. Edward W. Marti,Eric E. Peterson,Fernando Jose Garcia Marques,Abel Bermudez,Yi Wei,Rosalie Nolley,Nathan Lam,Alex LaPat Polasko,Chun-Lung Chiu,Dalin Zhang,Sanghee Cho,Grigorios Marios Karageorgos,Elizabeth McDonough,Chrystal Chadwick,Fiona Ginty,Kyeong Joo Jung,Raghu Machiraju,Parag Mallick,Laura Crowley,Jonathan R. Pollack,Hongjuan Zhao,Sharon J. Pitteri,James D. Brooks
DOI: https://doi.org/10.1186/s12967-024-05183-x
IF: 8.44
2024-04-25
Journal of Translational Medicine
Abstract:Loss of AZGP1 expression is a biomarker associated with progression to castration resistance, development of metastasis, and poor disease-specific survival in prostate cancer. However, high expression of AZGP1 cells in prostate cancer has been reported to increase proliferation and invasion. The exact role of AZGP1 in prostate cancer progression remains elusive.
medicine, research & experimental